Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate and Eculizumab

• Generic Name: cobicistat / darunavir / emtricitabine / tenofovir alafenamide
• Dosage Forms: n.a.
• Other Brand Names: Symtuza

Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate is a four-drug combination of darunavir (DRV), an HIV-1 protease inhibitor, cobicistat (COBI), a CYP3A inhibitor, and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 NRTIs, and is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.

• Generic Name: eculizumab
• Dosage Forms: n.a.
• Other Brand Names: Soliris

Eculizumab is a monoclonal antibody. Eculizumab binds to proteins in the blood that can destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells.

Eculizumab is used to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Eculizumab is also used to treat a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) in adults and children who weigh at least 11 pounds (5 kilograms).

Eculizumab is also used to treat myasthenia gravis in adults.

Eculizumab is also used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults.

Eculizumab is available only under a special program. You must be registered in the program and understand the risks and benefits of eculizumab.

Eculizumab may also be used for purposes not listed in this medication guide.